Plain-English translation of NCT07522073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Solid Tumors research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called , when combined with standard chemotherapy, works better than chemotherapy alone for people with advanced pancreatic cancer. Your cancer has a specific genetic change (called KRAS G12D) that this medication is designed to target. About half of participants will receive the medication along with chemotherapy, and half will receive chemotherapy with a placebo (a dummy pill that looks real but has no medicine in it).
Pancreatic cancer is very difficult to treat, and many people don't respond well to chemotherapy alone. This medication is designed to work against a specific genetic change found in some pancreatic cancers, so researchers want to see if adding it to standard chemotherapy can help people live longer and control their disease better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or a placebo, both combined with chemotherapy that your doctor will choose based on what's best for you. You will visit the hospital or clinic regularly to receive your chemotherapy infusions, take your daily medication (or placebo) by mouth, and have blood tests and imaging scans to monitor how well the treatment is working and check for side effects. The study will continue as long as the treatment is helping your cancer and you're tolerating it well.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States